Chromodomain helicase DNA-binding proteins in stem cells and human developmental diseases

Stem Cells and Development

Volumn 24, Issue 8, 2015, Pages 917-926

  Micucci, Joseph A ^a   Sperry, Ethan D ^b   Martin, Donna M ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; HELICASE; HELICASE DNA BINDING PROTEIN; UNCLASSIFIED DRUG; DNA HELICASE;

AUTISM; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELL PROLIFERATION; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DNA BINDING; EMBRYONIC STEM CELL; EPILEPSY; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; INTELLECTUAL IMPAIRMENT; MESENCHYMAL STEM CELL; MORBIDITY; MORTALITY; NEOPLASM; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEUROLOGIC DISEASE; NUCLEOSOME; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; STEM CELL; SYNDROME CHARGE; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; AUTISM SPECTRUM DISORDER; CHARGE SYNDROME; DNA HELICASES; DNA-BINDING PROTEINS; EPILEPSY; HUMANS; STEM CELLS;

EID: 84926435492     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0544     Document Type: Review

References (101)

1. de la Serna IL, Y Ohkawa and AN Imbalzano. (2006). Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 7:461-473.
2. Smith CL and CL Peterson. (2005). ATP-dependent chromatin remodeling. Curr Top Dev Biol 65:115-148.
3. Hall JA and PT Georgel. (2007). CHD proteins: a diverse family with strong ties. Biochem Cell Biol 85:463-476.
4. Layman WS, EA Hurd and DM Martin. (2010). Chromodomain proteins in development: lessons from CHARGE syndrome. Clin Genet 78:11-20.
5. Li W and AA Mills. (2014). Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes. Epigenomics 6:381-395.
6. Ball LJ, NV Murzina, RW Broadhurst, AR Raine, SJ Archer, FJ Stott, AG Murzin, PB Singh, PJ Domaille and ED Laue. (1997). Structure of the chromatin binding (chromo) domain from mouse modifier protein 1. EMBO J 16:2473-2481.
7. Pearce JJ, PB Singh and SJ Gaunt. (1992). The mouse has a Polycomb-like chromobox gene. Development 114:921-929.
8. Wreggett KA, F Hill, PS James, A Hutchings, GW Butcher and PB Singh. (1994). A mammalian homologue of Drosophila heterochromatin protein 1 (HP1) is a component of constitutive heterochromatin. Cytogenet Cell Genet 66:99-103.
9. Brehm A, SJ Nielsen, EA Miska, DJ McCance, JL Reid, AJ Bannister and T Kouzarides. (1999). The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 18:2449-2458.
10. Pray-Grant MG, JA Daniel, D Schieltz, JR Yates, 3rd and PA Grant. (2005). Chd1 chromodomain links histone H3 methylation with SAGA-and SLIK-dependent acetylation. Nature 433:434-438.
11. Flanagan JF, LZ Mi, M Chruszcz, M Cymborowski, KL Clines, Y Kim, W Minor, F Rastinejad and S Khorasanizadeh. (2005). Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 438:1181-1185.
12. Egan CM, U Nyman, J Skotte, G Streubel, S Turner, DJ O'Connell, V Rraklli, MJ Dolan, N Chadderton, et al. (2013). CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev Cell 26:223-236.
13. Hirschhorn JN, SA Brown, CD Clark and F Winston. (1992). Evidence that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chromatin structure. Genes Dev 6:2288-2298.
14. Winston F and M Carlson. (1992). Yeast SNF/SWI transcriptional activators and the SPT/SIN chromatin connection. Trends Genet 8:387-391.
15. Peterson CL, A Dingwall and MP Scott. (1994). Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proc Natl Acad Sci U S A 91:2905-2908.
16. Pazin MJ and JT Kadonaga. (1997). SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions? Cell 88:737-740.
17. Becker PB and W Horz. (2002). ATP-dependent nucleosome remodeling. Annu Rev Biochem 71:247-273.
18. Ryan DP, R Sundaramoorthy, D Martin, V Singh and T Owen-Hughes. (2011). The DNA-binding domain of the Chd1 chromatin-remodelling enzyme contains SANT and SLIDE domains. EMBO J 30:2596-2609.
19. Schuster EF and R Stoger. (2002). CHD5 defines a new subfamily of chromodomain-SWI2/SNF2-like helicases. Mamm Genome 13:117-119.
20. Aasland R, AF Stewart and T Gibson. (1996). The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor NCoR and TFIIIB. Trends Biochem Sci 21:87-88.
21. Boyer LA, RR Latek and CL Peterson. (2004). The SANT domain: a unique histone-tail-binding module? Nat Rev Mol Cell Biol 5:158-163.
22. Stokes DG and RP Perry. (1995). DNA-binding and chromatin localization properties of CHD1. Mol Cell Biol 15:2745-2753.
23. Liu JC, CG Gerreira and T Yusufzai. (2015). Human CHD2 is a chromatin assembly ATPase regulated by its chromo-and DNA-binding domains. J Biochem 290:25-34.
24. Bienz M. (2006). The PHD finger, a nuclear proteininteraction domain. Trends Biochem Sci 31:35-40.
25. Xue Y, J Wong, GT Moreno, MK Young, J Cote and W Wang. (1998). NURD, a novel complex with both ATPdependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2:851-861.
26. Musselman CA, J Ramirez, JK Sims, RE Mansfield, SS Oliver, JM Denu, JP Mackay, PA Wade, J Hagman and TG Kutateladze. (2012). Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4 ATPase is required for CHD4-mediated repression. Proc Natl Acad Sci U S A 109:787-792.
27. Mansfield RE, CA Musselman, AH Kwan, SS Oliver, AL Garske, F Davrazou, JM Denu, TG Kutateladze and JP Mackay. (2011). Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. J Biol Chem 286:11779-11791.
28. Musselman CA, RE Mansfield, AL Garske, F Davrazou, AH Kwan, SS Oliver, H O'Leary, JM Denu, JP Mackay and TG Kutateladze. (2009). Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem J 423:179-187.
29. Daubresse G, R Deuring, L Moore, O Papoulas, I Zakrajsek, WR Waldrip, MP Scott, JA Kennison and JW Tamkun. (1999). The Drosophila kismet gene is related to chromatin-remodeling factors and is required for both segmentation and segment identity. Development 126: 1175-1187.
30. Gaspar-Maia A, A Alajem, F Polesso, R Sridharan, MJ Mason, A Heidersbach, J Ramalho-Santos, MT McManus, K Plath, E Meshorer and M Ramalho-Santos. (2009). Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460:863-868.
31. Lin JJ, LW Lehmann, G Bonora, R Sridharan, AA Vashisht, N Tran, K Plath, JA Wohlschlegel and M Carey. (2011). Mediator coordinates PIC assembly with recruitment of CHD1. Genes Dev 25:2198-2209.
32. Zentner GE, PJ Tesar and PC Scacheri. (2011). Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 21:1273-1283.
33. Azuara V, P Perry, S Sauer, M Spivakov, HF Jorgensen, RM John, M Gouti, M Casanova, G Warnes, M Merkenschlager and AG Fisher. (2006). Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8:532-538.
34. Bernstein BE, TS Mikkelsen, X Xie, M Kamal, DJ Huebert, J Cuff, B Fry, A Meissner, M Wernig, et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315-326.
35. Zhou VW, A Goren and BE Bernstein. (2011). Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:7-18.
36. Ralston SH and B de Crombrugghe. (2006). Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492-2506.
37. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nature reviews. Immunology 8:726-736.
38. Chamberlain G, J Fox, B Ashton and J Middleton. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25:2739-2749.
39. Harada A, S Okada, D Konno, J Odawara, T Yoshimi, S Yoshimura, H Kumamaru, H Saiwai, T Tsubota, et al. (2012). Chd2 interacts with H3.3 to determine myogenic cell fate. EMBO J 31:2994-3007.
40. Shur I and D Benayahu. (2005). Characterization and functional analysis of CReMM, a novel chromodomain helicase DNA-binding protein. J Mol Biol 352:646-655.
41. Shur I, R Socher and D Benayahu. (2006). In vivo association of CReMM/CHD9 with promoters in osteogenic cells. J Cell Physiol 207:374-378.
42. Kondo M, AJ Wagers, MG Manz, SS Prohaska, DC Scherer, GF Beilhack, JA Shizuru and IL Weissman. (2003). Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 21:759-806.
43. Ugarte F and EC Forsberg. (2013). Haematopoietic stem cell niches: new insights inspire new questions. EMBO J 32:2535-2547.
44. Yoshida T, I Hazan, J Zhang, SY Ng, T Naito, HJ Snippert, EJ Heller, X Qi, LN Lawton, CJ Williams and K Georgopoulos. (2008). The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage differentiation. Genes Dev 22:1174-1189.
45. Cao R, L Wang, H Wang, L Xia, H Erdjument-Bromage, P Tempst, RS Jones and Y Zhang. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039-1043.
46. Sparmann A, Y Xie, E Verhoeven, M Vermeulen, C Lancini, G Gargiulo, D Hulsman, M Mann, JA Knoblich and M van Lohuizen. (2013). The chromodomain helicase Chd4 is required for Polycomb-mediated inhibition of astroglial differentiation. EMBO J 32:1598-1612.
47. Yamada T, Y Yang, M Hemberg, T Yoshida, HY Cho, JP Murphy, D Fioravante, WG Regehr, SP Gygi, K Georgopoulos and A Bonni. (2014). Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain. Neuron 83:122-134.
48. Micucci JA, WS Layman, EA Hurd, ED Sperry, SF Frank, MA Durham, DL Swiderski, JM Skidmore, PC Scacheri, Y Raphael and DM Martin. (2014). CHD7 and retinoic acid signaling cooperate to regulate neural stem cell and inner ear development in mouse models of CHARGE syndrome. Hum Mol Genet 23:434-448.
49. Feng W, MA Khan, P Bellvis, Z Zhu, O Bernhardt, C Herold-Mende and HK Liu. (2013). The chromatin remodeler CHD7 regulates adult neurogenesis via activation of soxc transcription factors. Cell Stem Cell 13:62-72.
50. Jones KM, N Saric, JP Russell, CL Andoniadou, PJ Scambler and MA Basson. (2015). CHD7 maintains neural stem cell quiescence and prevents premature stem cell depletion in the adult hippocampus. Stem Cells 33:196-210.
51. Layman WS, EA Hurd and DM Martin. (2011). Reproductive dysfunction and decreased GnRH neurogenesis in a mouse model of CHARGE syndrome. Hum Mol Genet 20:3138-3150.
52. Hurd EA, HK Poucher, K Cheng, Y Raphael and DM Martin. (2010). The ATP-dependent chromatin remodeling enzyme CHD7 regulates pro-neural gene expression and neurogenesis in the inner ear. Development 137: 3139-3150.
53. Issekutz KA, JM Graham, Jr., C Prasad, IM Smith and KD Blake. (2005). An epidemiological analysis of CHARGE syndrome: preliminary results from a Canadian study. Am J Med Genet A 133:309-317.
54. Vissers LE, CM van Ravenswaaij, R Admiraal, JA Hurst, BB de Vries, IM Janssen, WA van der Vliet, EH Huys, PJ de Jong, et al. (2004). Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 36:955-957.
55. Bergman JE, N Janssen, LH Hoefsloot, MC Jongmans, RM Hofstra and CM van Ravenswaaij-Arts. (2011). CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J Med Genet 48:334-342.
56. Janssen N, JE Bergman, MA Swertz, L Tranebjaerg, M Lodahl, J Schoots, RM Hofstra, CM van Ravenswaaij-Arts and LH Hoefsloot. (2012). Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat 33:1149-1160.
57. Bouazoune K and RE Kingston. (2012). Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders. Proc Natl Acad Sci U S A 109:19238-19243.
58. Hurd EA, PL Capers, MN Blauwkamp, ME Adams, Y Raphael, HK Poucher and DM Martin. (2007). Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple developing tissues. Mamm Genome 18:94-104.
59. Adams ME, EA Hurd, LA Beyer, DL Swiderski, Y Raphael and DM Martin. (2007). Defects in vestibular sensory epithelia and innervation in mice with loss of Chd7 function: implications for human CHARGE syndrome. J Comp Neurol 504:519-532.
60. Pinto G, V Abadie, R Mesnage, J Blustajn, S Cabrol, J Amiel, L Hertz-Pannier, AM Bertrand, S Lyonnet, R Rappaport and I Netchine. (2005). CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J Clin Endocrinol Metab 90:5621-5626.
61. Layman WS, DP McEwen, LA Beyer, SR Lalani, SD Fernbach, E Oh, A Swaroop, CC Hegg, Y Raphael, JR Martens and DM Martin. (2009). Defects in neural stem cell proliferation and olfaction in Chd7 deficient mice indicate a mechanism for hyposmia in human CHARGE syndrome. Hum Mol Genet 18:1909-1923.
62. Legendre M, M Gonzales, G Goudefroye, F Bilan, P Parisot, MJ Perez, M Bonniere, B Bessieres, J Martinovic, et al. (2012). Antenatal spectrum of CHARGE syndrome in 40 fetuses with CHD7 mutations. J Med Genet 49:698-707.
63. Bergman JE, EA Bosman, CM van Ravenswaaij-Arts and KP Steel. (2010). Study of smell and reproductive organs in a mouse model for CHARGE syndrome. Eur J Hum Genet 18:171-177.
64. Engelen E, U Akinci, JC Bryne, J Hou, C Gontan, M Moen, D Szumska, C Kockx, W van Ijcken, et al. (2011). Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet 43:607-611.
65. Pagon RA, JM Graham, Jr., J Zonana and SL Yong. (1981). Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr 99:223-227.
66. Chenier S, G Yoon, B Argiropoulos, J Lauzon, R Laframboise, JW Ahn, CM Ogilvie, AC Lionel, CR Marshall, et al. (2014). CHD2 haploinsufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems. J Neurodev Disord 6:9.
67. Epi KC, Epilepsy Phenome/Genome Project, AS Allen, SF Berkovic, P Cossette, N Delanty, D Dlugos, EE Eichler, MP Epstein, et al. (2013). De novo mutations in epileptic encephalopathies. Nature 501:217-221.
68. Carvill GL, SB Heavin, SC Yendle, JM McMahon, BJ O'Roak, J Cook, A Khan, MO Dorschner, M Weaver, et al. (2013). Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 45:825-830.
69. Neale BM, Y Kou, L Liu, A Ma'ayan, KE Samocha, A Sabo, CF Lin, C Stevens, LS Wang, et al. (2012). Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485:242-245.
70. O'Roak BJ, L Vives, S Girirajan, E Karakoc, N Krumm, BP Coe, R Levy, A Ko, C Lee, et al. (2012). Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485:246-250.
71. Tucker T, FR Zahir, M Griffith, A Delaney, D Chai, E Tsang, E Lemyre, S Dobrzeniecka, M Marra, et al. (2014). Single exon-resolution targeted chromosomal microarray analysis of known and candidate intellectual disability genes. Eur J Hum Genet 22:792-800.
72. Jiang YH, RK Yuen, X Jin, M Wang, N Chen, X Wu, J Ju, J Mei, Y Shi, et al. (2013). Detection of clinically relevant genetic variants in autism spectrum disorder by wholegenome sequencing. Am J Hum Genet 93:249-263.
73. Yamada K, D Fukushi, T Ono, Y Kondo, R Kimura, N Nomura, KJ Kosaki, Y Yamada, S Mizuno and N Wakamatsu. (2010). Characterization of a de novo balanced t(4;20)(q33;q12) translocation in a patient with mental retardation. Am J Med Genet A 152A:3057-3067.
74. Sugathan A, M Biagioli, C Golzio, S Erdin, I Blumenthal, P Manavalan, A Ragavendran, H Brand, D Lucente, et al. (2014). CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. Proc Natl Acad Sci U S A 111:E4468-E4477.
75. Bernier R, C Golzio, B Xiong, HA Stessman, BP Coe, O Penn, K Witherspoon, J Gerdts, C Baker, et al. (2014). Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158:263-276.
76. Krumm N, BJ O'Roak, J Shendure and EE Eichler. (2014). A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci 37:95-105.
77. O'Roak BJ, L Vives, W Fu, JD Egertson, IB Stanaway, IG Phelps, G Carvill, A Kumar, C Lee, et al. (2012). Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338:1619-1622.
78. Suls A, JA Jaehn, A Kecskes, Y Weber, S Weckhuysen, DC Craiu, A Siekierska, T Djemie, T Afrikanova, et al. (2013). De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 93:967-975.
79. Nishiyama M, K Oshikawa, Y Tsukada, T Nakagawa, S Iemura, T Natsume, Y Fan, A Kikuchi, AI Skoultchi and KI Nakayama. (2009). CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat Cell Biol 11:172-182.
80. Sakamoto I, S Kishida, A Fukui, M Kishida, H Yamamoto, S Hino, T Michiue, S Takada, M Asashima and A Kikuchi. (2000). A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J Biol Chem 275:32871-32878.
81. Nishiyama M, K Nakayama, R Tsunematsu, T Tsukiyama, A Kikuchi and KI Nakayama. (2004). Early embryonic death in mice lacking the beta-catenin-binding protein Duplin. Mol Cell Biol 24:8386-8394.
82. Batsukh T, L Pieper, AM Koszucka, N von Velsen, S Hoyer-Fender, M Elbracht, JE Bergman, LH Hoefsloot and S Pauli. (2010). CHD8 interacts with CHD7, a protein which is mutated in CHARGE syndrome. Hum Mol Genet 19:2858-2866.
83. Van Nostrand JL, CA Brady, H Jung, DR Fuentes, MM Kozak, TM Johnson, CY Lin, CJ Lin, DL Swiderski, et al. (2014). Inappropriate p53 activation during development induces features of CHARGE syndrome. Nature 514:228-232.
84. Liu W, J Lindberg, G Sui, J Luo, L Egevad, T Li, C Xie, M Wan, ST Kim, et al. (2012). Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 31:3939-3948.
85. Huang S, ZG Gulzar, K Salari, J Lapointe, JD Brooks and JR Pollack. (2012). Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31:4164-4170.
86. Le Gallo M, AJ O'Hara, ML Rudd, ME Urick, NF Hansen, NJ O'Neil, JC Price, S Zhang, BM England, et al. (2012). Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatinremodeling and ubiquitin ligase complex genes. Nat Genet 44:1310-1315.
87. Zhuang T, RA Hess, V Kolla, M Higashi, TD Raabe and GM Brodeur. (2014). CHD5 is required for spermiogenesis and chromatin condensation. Mech Dev 131:35-46.
88. Kolla V, T Zhuang, M Higashi, K Naraparaju and GM Brodeur. (2014). Role of CHD5 in human cancers: 10 years later. Cancer Res 74:652-658.
89. Thompson PM, T Gotoh, M Kok, PS White and GM Brodeur. (2003). CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22:1002-1011.
90. Gui Y, G Guo, Y Huang, X Hu, A Tang, S Gao, R Wu, C Chen, X Li, et al. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43:875-878.
91. Mouradov D, C Sloggett, RN Jorissen, CG Love, S Li, AW Burgess, D Arango, RL Strausberg, D Buchanan, et al. (2014). Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 74:3238-3247.
92. Stanley FK, S Moore and AA Goodarzi. (2013). CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res 750:31-44.
93. Kim MS, NG Chung, MR Kang, NJ Yoo and SH Lee. (2011). Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 58:660-668.
94. Kulkarni S, P Nagarajan, J Wall, DJ Donovan, RL Donell, AH Ligon, S Venkatachalam and BJ Quade. (2008). Disruption of chromodomain helicase DNA binding protein 2 (CHD2) causes scoliosis. Am J Med Genet A 146A:1117-1127.
95. Gao X, D Gordon, D Zhang, R Browne, C Helms, J Gillum, S Weber, S Devroy, S Swaney, et al. (2007). CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis. Am J Hum Genet 80:957-965.
96. Marfella CG, Y Ohkawa, AH Coles, DS Garlick, SN Jones and AN Imbalzano. (2006). Mutation of the SNF2 family member Chd2 affects mouse development and survival. J Cell Physiol 209:162-171.
97. Nagarajan P, TM Onami, S Rajagopalan, S Kania, R Donnell and S Venkatachalam. (2009). Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 28: 1053-1062.
98. Ge Q, DS Nilasena, CA O'Brien, MB Frank and IN Targoff. (1995). Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest 96:1730-1737.
99. Bagchi A, C Papazoglu, Y Wu, D Capurso, M Brodt, D Francis, M Bredel, H Vogel and AA Mills. (2007). CHD5 is a tumor suppressor at human 1p36. Cell 128:459-475.
100. Quan J and T Yusufzai. (2014). The tumor suppressor chromodomain helicase dna-binding protein 5 (CHD5) remodels nucleosomes by unwrapping. J Biol Chem 289: 20717-20726.
101. Bajpai R, DA Chen, A Rada-Iglesias, J Zhang, Y Xiong, J Helms, CP Chang, Y Zhao, T Swigut and J Wysocka. (2010). CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature 463:958-962.